Ex-Genentech exec named as new Juno Therapeutics CIO
pharmafile | January 8, 2018 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | appointment, juno therapeutics
Biopharmaceutical firm and cellular immunotherapy specialist Juno Therapeutics has named Cindy Elkins as its new Chief Information Officer, where she will report to President and CEO Hans Bishop.
Elkins joins the company from Genentech, where she served as Vice President, IT for the Americas, leading the firm’s US commercial technology integration after its acquisition by Roche. She is credited as instrumental in Genentech becoming the first biotech to implement several key technology platforms on a large scale, while also maintaining consistent experience for more than 44,000 users.
Previous to her time with Genentech, Elkins served at software and IT firm Ariba, where she held the position of Vice President and General Manager.
“Cindy is a leader with a track record of increasing the impact of information technology in the biotech industry, focusing on innovation and delivering advanced technologies that support the discovery of breakthrough therapies,” commented CEO Bishop. “Her talent, passion and experience will help us advance our mission to bring better medicines to patients.”
Elkins herself commented: “I am delighted to join Juno, a company that reflects my passion for vibrant, accountable, high-performing organisations seeking to transform and innovate at scale. It is an honour to be a part of a mission to fundamentally change the way cancer and other diseases are treated, and to provide the tools and infrastructure to allow Juno’s employees to do their best work.”
Related Content
TQ Therapeutics acquires Juno GmbH to support decentralised cell therapy platform
TQ Therapeutics (TQx) has acquired Juno Therapeutics GmbH, the German subsidiary of Juno Therapeutics, through …
David Wheadon appointed to board of directors at Seaport Therapeutics
This week, Seaport Therapeutics have appointed David Wheadon MD to their board of directors.
Myeloma UK reveals new Director of Research appointment
UK non-profit organisation Myeloma UK has selected Sarah McDonald as its new Director of Research, …
